California State Teachers Retirement System Acquires 7,629 Shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

California State Teachers Retirement System increased its position in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) by 25.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 37,087 shares of the company's stock after acquiring an additional 7,629 shares during the quarter. California State Teachers Retirement System owned about 0.06% of Harmony Biosciences worth $1,276,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. GF Fund Management CO. LTD. bought a new position in Harmony Biosciences in the fourth quarter valued at approximately $41,000. KBC Group NV lifted its stake in Harmony Biosciences by 79.9% in the fourth quarter. KBC Group NV now owns 1,844 shares of the company's stock valued at $63,000 after buying an additional 819 shares in the last quarter. PNC Financial Services Group Inc. lifted its stake in Harmony Biosciences by 28.7% in the fourth quarter. PNC Financial Services Group Inc. now owns 2,328 shares of the company's stock valued at $80,000 after buying an additional 519 shares in the last quarter. Virtus Investment Advisers Inc. bought a new position in Harmony Biosciences in the fourth quarter valued at approximately $124,000. Finally, Summit Investment Advisors Inc. lifted its stake in Harmony Biosciences by 34.8% in the fourth quarter. Summit Investment Advisors Inc. now owns 3,987 shares of the company's stock valued at $137,000 after buying an additional 1,029 shares in the last quarter. Institutional investors own 86.23% of the company's stock.

Harmony Biosciences Stock Down 1.1%

HRMY traded down $0.36 during trading on Friday, reaching $32.97. 786,752 shares of the stock were exchanged, compared to its average volume of 622,510. The stock has a market cap of $1.89 billion, a P/E ratio of 15.63, a price-to-earnings-growth ratio of 0.47 and a beta of 0.87. Harmony Biosciences Holdings, Inc. has a twelve month low of $26.47 and a twelve month high of $41.61. The stock's 50 day moving average price is $32.14 and its two-hundred day moving average price is $34.09. The company has a debt-to-equity ratio of 0.28, a quick ratio of 3.20 and a current ratio of 3.24.

Harmony Biosciences (NASDAQ:HRMY - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The company reported $0.78 EPS for the quarter, topping analysts' consensus estimates of $0.59 by $0.19. Harmony Biosciences had a net margin of 17.98% and a return on equity of 23.16%. The firm had revenue of $184.73 million during the quarter, compared to analysts' expectations of $184.26 million. During the same period in the previous year, the business posted $0.67 earnings per share. The company's revenue for the quarter was up 19.5% compared to the same quarter last year. Equities analysts expect that Harmony Biosciences Holdings, Inc. will post 2.43 EPS for the current year.

Analyst Upgrades and Downgrades

HRMY has been the topic of a number of research reports. Mizuho lifted their price target on shares of Harmony Biosciences from $44.00 to $48.00 and gave the company an "outperform" rating in a research note on Thursday, May 15th. HC Wainwright reiterated a "buy" rating and issued a $70.00 price objective on shares of Harmony Biosciences in a report on Tuesday, April 8th. Needham & Company LLC reiterated a "buy" rating and issued a $49.00 price objective on shares of Harmony Biosciences in a report on Tuesday, May 6th. Cantor Fitzgerald upgraded shares of Harmony Biosciences to a "strong-buy" rating in a report on Tuesday, May 13th. Finally, UBS Group lowered their price objective on shares of Harmony Biosciences from $55.00 to $48.00 and set a "buy" rating on the stock in a report on Monday, April 28th. Eight equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of "Buy" and a consensus target price of $53.00.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.